GHK-Cu, free GHK and the copper between them
A small change in the name can mean a different substance. Copper makes that distinction particularly interesting.
GHK and its copper complex
GHK is a short chain of glycine, histidine and lysine. GHK-Cu is that tripeptide bound to a copper ion; copper tripeptide-1 is its cosmetic ingredient name. The skin-regeneration review describes the GHK sequence in collagen and in SPARC, a matrix protein, and follows the tissue-remodelling research.
The origin is stranger than a skincare ingredient list suggests. GHK was isolated from human plasma in 1973 by Loren Pickart as a factor that prompted aged liver tissue to make proteins more like younger tissue. Later work explored the copper complex in repair and skin biology. I like that history because it starts with an observed effect and a search for its source, well before the cosmetic reputation.
Copper coordination matters for many reported matrix-remodelling effects. Free GHK and GHK-Cu nevertheless both appear in the literature, and some gene-level claims concern GHK. A bare tripeptide and a copper complex deserve separate identities.
Collagen, elastin and remodelling
In cell-culture work discussed in the 2015 review, GHK-Cu stimulated fibroblasts, the cells that maintain connective tissue, to make collagen and other matrix components in vitro. It also discusses enzymes that break down matrix and the inhibitors that restrain them. Repair involves renewal as well as production; “more collagen” leaves out much of that activity.
Small topical human studies reported improvements in skin laxity, fine lines, wrinkle depth and density. The review reports increased collagen production in 70% of treated women, compared with 50% for vitamin C and 40% for retinoic acid. Those percentages describe the proportions with an increase in that comparison. They do not describe how much collagen each person gained.
The topical skin findings have earned my interest. A universal anti-aging claim would need considerably more: stronger replication, larger human trials and outcomes extending beyond the local skin measures studied here. Much of the foundational literature comes from Pickart and colleagues, which makes broader replication especially useful.
What crossed the skin?
In the human skin-layer experiment, skin was studied outside the body. Over 48 hours, 136.2 ± 17.5 micrograms/cm² of copper permeated dermatomed skin, and 97 ± 6.6 micrograms/cm² was retained as a dermal depot. The measured material was copper. The preparation of the skin also matters when interpreting those values.
The 2025 delivery review describes poor passage through the stratum corneum, the skin’s outer barrier, as a major practical problem. It considers changes to the peptide and delivery systems intended to improve passage. A formulation that changes penetration has changed an important condition of the experiment.
I’d welcome an experiment following the intact complex all the way to the cells of interest. For now, these copper measurements and formulation studies are more useful when their different questions remain visible. A cream, a modified peptide and an injectable preparation each require their own evidence.
The 5-ALA + GHK trial
The hair-growth trial tested a complex of 5-aminolevulinic acid and GHK in 45 men with androgenetic alopecia over 6 months. Hair-count increases were 52.6 at the studied concentration of 100 mg/mL and 71.5 at 50 mg/mL, compared with 9.6 for placebo, with p<0.05. No adverse events were reported in any group.
Those are findings for the tested topical combination. The design does not establish how much GHK contributed, and it did not test pure GHK-Cu. The lower studied concentration also had the larger increase; a tidy “more ingredient, more effect” account would misdescribe the reported values.
This result merits an entry as controlled human evidence for a GHK-containing preparation. Giving the same credit to every copper-peptide formulation would make the catalogue less accurate. The home comparison figure shows the results with the formulation still attached.
GHK gene data
The 2018 gene-data review discusses GHK-associated changes in gene expression from Connectivity Map analyses. It reports approximately 31.2% of human genes at a 50%-or-greater change threshold, with 59% of affected genes increased and 41% decreased. This is database and cell-level evidence, rather than a trial showing rejuvenation in people.
The much repeated “approximately 4,000 genes” claim uses a broader extrapolation; the 50% threshold table concerns on the order of 2,100 genes. Thresholds decide which changes enter a count. I’m sceptical of treating a large gene count as a measure of clinical benefit when the patient outcome has yet to be measured.
Gene-expression patterns can suggest experiments worth doing. Demonstrating the corresponding protein changes and useful effects in living humans would be a substantial next step.
Topical safety and systemic gaps
Topical copper tripeptide-1 is a legal cosmetic ingredient in the US, EU and UK. GHK-Cu has no FDA- or EMA-approved therapeutic indication. Injectable or systemic GHK-Cu has no FDA approval; prescription access depends on individual clinical assessment and applicable compounding rules. Human pharmacokinetic data have not established a validated systemic half-life or a dosing basis.
The formulation review discusses compatibility and stability: ascorbic acid and low-pH conditions can disrupt the copper complex. The literature also includes local pigmentation concerns in some copper-peptide applications. Prolonged systemic use raises a theoretical copper-balance concern; the source record reports no human copper-toxicity cases attributed to GHK-Cu. The distinction between a theoretical risk and an observed event matters here too.
Community accounts of firmer-feeling skin, smoother texture, irritation and darker spots are anecdotal accounts, not clinical evidence. They describe perceptions around different formulations and cannot settle either efficacy or safety. The uneven experiences are worth recording; the topical studies and reviews carry the argument about measured effects.